[M04AX02, pegloticase, The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegvisomant.]
[M03AB01, succinylcholine, The metabolism of Succinylcholine can be decreased when combined with Pegvisomant.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfisoxazole.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glymidine.]
[N05CA19, thiopental, The therapeutic efficacy of Thiopental can be decreased when used in combination with Pegvisomant.]
[G04BE06, moxisylyte, Pegvisomant may increase the neuromuscular blocking activities of Moxisylyte.]
[N02AX01, tilidine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, Pegvisomant may increase the bradycardic activities of Timolol.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tolazamide.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tolbutamide.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Pegvisomant.]
[S01BA05, triamcinolone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Triamcinolone.]
[A03AB12, mepenzolate, The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Pegvisomant.]
[N05AA05, triflupromazine, The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Pegvisomant.]
[D07AC02, fluclorolone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluclorolone.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Pegvisomant.]
[R03BA07, mometasone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Mometasone.]
[A03AA05, trimebutine, The therapeutic efficacy of Trimebutine can be decreased when used in combination with Pegvisomant.]
[C02BA01, trimethaphan, Pegvisomant may increase the neuromuscular blocking activities of Trimethaphan.]
[A03BB01, butylscopolamine, The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Pegvisomant.]
[M03AA02, tubocurarine, Pegvisomant may increase the neuromuscular blocking activities of Tubocurarine.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Linagliptin.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Pegvisomant.]
[B01AA03, warfarin, The metabolism of Warfarin can be increased when combined with Pegvisomant.]
[N05AE04, ziprasidone, The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Pegvisomant.]
[G04BD07, tolterodine, The therapeutic efficacy of Tolterodine can be decreased when used in combination with Pegvisomant.]
[C07AB03, atenolol, Pegvisomant may increase the bradycardic activities of Atenolol.]
[L03AB11, peginterferon alfa-2a, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Peginterferon alfa-2a.]
[M03AC04, atracurium, The therapeutic efficacy of Atracurium can be decreased when used in combination with Pegvisomant.]
[S01FA01, atropine, The therapeutic efficacy of Atropine can be decreased when used in combination with Pegvisomant.]
[H02AB11, prednylidene, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednylidene.]
[B03XA04, peginesatide, The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegvisomant.]
[G04BD12, mirabegron, Pegvisomant may increase the neuromuscular blocking activities of Mirabegron.]
[H02AA01, aldosterone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Aldosterone.]
[N05CA04, barbital, The therapeutic efficacy of Barbital can be decreased when used in combination with Pegvisomant.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Pegvisomant.]
[R06AC06, thonzylamine, The therapeutic efficacy of Thonzylamine can be decreased when used in combination with Pegvisomant.]
[G04BD10, darifenacin, The therapeutic efficacy of Darifenacin can be decreased when used in combination with Pegvisomant.]
[H01CB05, pasireotide, The risk or severity of increased transaminases can be increased when Pasireotide is combined with Pegvisomant.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Alogliptin.]
[A10BK02, canagliflozin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Canagliflozin.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin detemir.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pramlintide.]
[N04AC01, benztropine, The therapeutic efficacy of Benzatropine can be decreased when used in combination with Pegvisomant.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Pegvisomant.]
[L03AA14, lipegfilgrastim, The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegvisomant.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lixisenatide.]
[A10BK01, dapagliflozin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dapagliflozin.]
[C07AB04, acebutolol, Pegvisomant may increase the bradycardic activities of Acebutolol.]
[S03BA03, betamethasone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Betamethasone.]
[S01ED02, betaxolol, Pegvisomant may increase the bradycardic activities of Betaxolol.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Albiglutide.]
[A03BA03, hyoscyamine, The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Pegvisomant.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be increased when combined with Pegvisomant.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Empagliflozin.]
[L03AB13, peginterferon beta-1a, The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegvisomant.]
[D11AA01, glycopyrronium, The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Pegvisomant.]
[V04CX03, methacholine, The risk or severity of adverse effects can be increased when Pegvisomant is combined with Methacholine.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dulaglutide.]
[A06AH03, naloxegol, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Naloxegol.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Pegvisomant.]
[A03AA09, difemerine, The therapeutic efficacy of Difemerine can be decreased when used in combination with Pegvisomant.]
[A07DA06, eluxadoline, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Eluxadoline.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Acarbose.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin degludec.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Acetohexamide.]
[N05CA05, aprobarbital, The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Pegvisomant.]
[N04BC01, bromocriptine, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Bromocriptine.]
[R06AB01, brompheniramine, The therapeutic efficacy of Brompheniramine can be decreased when used in combination with Pegvisomant.]
[C07AA19, bupranolol, Pegvisomant may increase the bradycardic activities of Bupranolol.]
[N07BC01, buprenorphine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine.]
[N02AF01, butorphanol, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Butorphanol.]
[R03CC12, bambuterol, Pegvisomant may increase the neuromuscular blocking activities of Bambuterol.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pregabalin.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Benfluorex.]
[S01HA02, benoxinate, Pegvisomant may increase the neuromuscular blocking activities of Oxybuprocaine.]
[R05DB01, benzonatate, Pegvisomant may increase the neuromuscular blocking activities of Benzonatate.]
[N07AB02, bethanechol, The risk or severity of adverse effects can be increased when Pegvisomant is combined with Bethanechol.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Pegvisomant is combined with Acetylcholine.]
[C07AB07, bisoprolol, Pegvisomant may increase the bradycardic activities of Bisoprolol.]
[C07AA17, bopindolol, Pegvisomant may increase the bradycardic activities of Bopindolol.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Pegvisomant.]
[R03BA02, budesonide, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Budesonide.]
[N05CA03, butobarbital, The therapeutic efficacy of Butobarbital can be decreased when used in combination with Pegvisomant.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Semaglutide.]
[A10BK04, ertugliflozin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ertugliflozin.]
[S01EB02, carbachol, The risk or severity of adverse effects can be increased when Pegvisomant is combined with Carbamoylcholine.]
[A03AA03, camylofine, The therapeutic efficacy of Camylofin can be decreased when used in combination with Pegvisomant.]
[C07AG02, carvedilol, Pegvisomant may increase the bradycardic activities of Carvedilol.]
[A16AB19, pegvaliase, The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegvisomant.]
[C07AB08, celiprolol, Pegvisomant may increase the bradycardic activities of Celiprolol.]
[L03AX21, elapegademase, The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegvisomant.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Carbutamide.]
[N01BA04, chloroprocaine, Pegvisomant may increase the neuromuscular blocking activities of Chloroprocaine.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Pegvisomant.]
[R03BB08, revefenacin, The therapeutic efficacy of Revefenacin can be decreased when used in combination with Pegvisomant.]
[N07XX05, amifampridine, The risk or severity of adverse effects can be increased when Pegvisomant is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Cibenzoline.]
[H02AB14, cloprednol, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cloprednol.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ubidecarenone.]
[H02AB17, cortivazol, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cortivazol.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin pork.]
[H02AB13, deflazacort, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Deflazacort.]
[N02AX03, dezocine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dezocine.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Pegvisomant.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Pegvisomant.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Pegvisomant.]
[S01AE06, gatifloxacin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gatifloxacin.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydrocodeine.]
[C08CA16, clevidipine, Pegvisomant may increase the neuromuscular blocking activities of Clevidipine.]
[A03AA08, dihexyverine, The therapeutic efficacy of Dihexyverine can be decreased when used in combination with Pegvisomant.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Pegvisomant.]
[D07XB03, fluprednidene, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluprednidene.]
[G04BD09, trospium, The therapeutic efficacy of Trospium can be decreased when used in combination with Pegvisomant.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Pegvisomant.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Pegvisomant.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Pegvisomant.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Pegvisomant.]
[R03BA03, flunisolide, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Flunisolide.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin human.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Pegvisomant.]
[L03AB10, peginterferon alfa-2b, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Peginterferon alfa-2b.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Citalopram.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gliquidone.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Pegvisomant.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Pegvisomant.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tirzepatide.]
[N05AH02, clozapine, The therapeutic efficacy of Clozapine can be decreased when used in combination with Pegvisomant.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sotagliflozin.]
[S02DA02, cocaine, Pegvisomant may increase the neuromuscular blocking activities of Cocaine.]
[R05DA04, codeine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Codeine.]
[M03AC05, hexafluorenium, The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Pegvisomant.]
[A03AB10, hexocyclium, The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Pegvisomant.]
[A03BB06, homatropine methylbromide, The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Pegvisomant.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Nateglinide.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin glargine.]
[R03BA08, ciclesonide, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ciclesonide.]
[R06AX27, desloratadine, The therapeutic efficacy of Desloratadine can be decreased when used in combination with Pegvisomant.]
[S02BA08, fluocinolone acetonide, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocinolone acetonide.]
[N03AX09, lamotrigine, The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Pegvisomant.]
[S01BA03, cortisone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cortisone.]
[A03AA04, mebeverine, The therapeutic efficacy of Mebeverine can be decreased when used in combination with Pegvisomant.]
[C07AA14, mepindolol, Pegvisomant may increase the bradycardic activities of Mepindolol.]
[H02AB15, meprednisone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meprednisone.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Pegvisomant.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Miglitol.]
[R06AX02, cyproheptadine, The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Pegvisomant.]
[C07AB12, nebivolol, Pegvisomant may increase the bradycardic activities of Nebivolol.]
[N06AX06, nefazodone, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Nefazodone.]
[M03AC11, cisatracurium, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Pegvisomant.]
[R05DA06, normethadone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Normethadone.]
[N06AB10, escitalopram, The therapeutic efficacy of Escitalopram can be decreased when used in combination with Pegvisomant.]
[G04BD08, solifenacin, The therapeutic efficacy of Solifenacin can be decreased when used in combination with Pegvisomant.]
[N06AA01, desipramine, The therapeutic efficacy of Desipramine can be decreased when used in combination with Pegvisomant.]
[D07XC02, desoximetasone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Desoximetasone.]
[H02AA03, desoxycorticosterone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Desoxycortone.]
[S03BA01, dexamethasone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dexamethasone.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Pegvisomant.]
[G04BD04, oxybutynin, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Pegvisomant.]
[A03AA01, oxyphencyclimine, The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Pegvisomant.]
[R05DA09, dextromethorphan, The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Pegvisomant.]
[N02AC01, dextromoramide, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextromoramide.]
[N06AB05, paroxetine, The therapeutic efficacy of Paroxetine can be decreased when used in combination with Pegvisomant.]
[N07BC06, heroin, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diamorphine.]
[A03AA07, dicyclomine, The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Pegvisomant.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pioglitazone.]
[A03AB14, pipenzolate, The therapeutic efficacy of Pipenzolate can be decreased when used in combination with Pegvisomant.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Pegvisomant.]
[L03AA13, pegfilgrastim, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegfilgrastim.]
[D07XC04, diflucortolone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Difluocortolone.]
[A03AB11, poldine, The therapeutic efficacy of Poldine can be decreased when used in combination with Pegvisomant.]
[L01XX24, pegaspargase, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegaspargase.]
[N02AA03, hydromorphone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone.]
[R06AB03, dimethindene, The therapeutic efficacy of Dimetindene can be decreased when used in combination with Pegvisomant.]
[R06AA02, diphenhydramine, The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Pegvisomant.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diphenoxylate.]
[B01AC07, dipyridamole, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dipyridamole.]
[C01BA03, disopyramide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Disopyramide.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sunitinib.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Pegvisomant.]
[N06AA16, dothiepin, The therapeutic efficacy of Dosulepin can be decreased when used in combination with Pegvisomant.]
[N06AA12, doxepin, The therapeutic efficacy of Doxepin can be decreased when used in combination with Pegvisomant.]
[R06AA09, doxylamine, The therapeutic efficacy of Doxylamine can be decreased when used in combination with Pegvisomant.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sertraline.]
[C07AB13, talinolol, Pegvisomant may increase the bradycardic activities of Talinolol.]
[H01AA01, corticotropin, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Corticotropin.]
[C07AA16, tertatolol, Pegvisomant may increase the bradycardic activities of Tertatolol.]
[G04BD01, emepronium, The therapeutic efficacy of Emepronium can be decreased when used in combination with Pegvisomant.]
[A03AB08, tridihexethyl, The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Pegvisomant.]
[H02CA01, trilostane, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Trilostane.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Pegvisomant.]
[S01FB02, ephedrine, Pegvisomant may increase the neuromuscular blocking activities of Ephedrine.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Venlafaxine.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin glulisine.]
[R03BA09, fluticasone furoate, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluticasone furoate.]
[R03BA05, fluticasone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluticasone.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Pegvisomant.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ethylmorphine.]
[R06AX12, terfenadine, The therapeutic efficacy of Terfenadine can be decreased when used in combination with Pegvisomant.]
[N06AB08, fluvoxamine, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Fluvoxamine.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Pegvisomant.]
[N02AB03, fentanyl, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fentanyl.]
[N07AX03, cevimeline, The risk or severity of adverse effects can be increased when Pegvisomant is combined with Cevimeline.]
[G04BD02, flavoxate, The therapeutic efficacy of Flavoxate can be decreased when used in combination with Pegvisomant.]
[H02AA02, fludrocortisone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fludrocortisone.]
[D07XB01, flumethasone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Flumethasone.]
[D07AC08, fluocinonide, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocinonide.]
[H02AB03, fluocortolone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocortolone.]
[S01CB05, fluorometholone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluorometholone.]
[N06AB03, fluoxetine, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Pegvisomant.]
[M03AA01, alcuronium, The therapeutic efficacy of Alcuronium can be decreased when used in combination with Pegvisomant.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Pegvisomant.]
[M03AC02, gallamine, The therapeutic efficacy of Gallamine can be decreased when used in combination with Pegvisomant.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Liraglutide.]
[N01AH02, alfentanil, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alfentanil.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glipizide.]
[C07AB09, esmolol, Pegvisomant may increase the bradycardic activities of Esmolol.]
[S01LA03, pegaptanib, The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegvisomant.]
[N05AH04, quetiapine, The therapeutic efficacy of Quetiapine can be decreased when used in combination with Pegvisomant.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin aspart.]
[L01CE02, irinotecan, Pegvisomant may increase the neuromuscular blocking activities of Irinotecan.]
[N05CA16, hexobarbital, The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Pegvisomant.]
[R05DA03, hydrocodone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone.]
[G04BD06, propiverine, The therapeutic efficacy of Propiverine can be decreased when used in combination with Pegvisomant.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Pegvisomant.]
[N01AH03, sufentanil, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, The therapeutic efficacy of Imipramine can be decreased when used in combination with Pegvisomant.]
[R01AD07, tixocortol, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tixocortol.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Indomethacin.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Pegvisomant.]
[A03AA30, piperidolate, The therapeutic efficacy of Piperidolate can be decreased when used in combination with Pegvisomant.]
[S01XA28, varenicline, The risk or severity of adverse effects can be increased when Pegvisomant is combined with Varenicline.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sitagliptin.]
[R06AE01, buclizine, The therapeutic efficacy of Buclizine can be decreased when used in combination with Pegvisomant.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Vildagliptin.]
[C07AA01, alprenolol, Pegvisomant may increase the bradycardic activities of Alprenolol.]
[L03AX04, pegademase bovine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegademase.]
[N01AB06, isoflurane, The therapeutic efficacy of Isoflurane can be decreased when used in combination with Pegvisomant.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Exenatide.]
[N05AH03, olanzapine, The therapeutic efficacy of Olanzapine can be decreased when used in combination with Pegvisomant.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lipoic acid.]
[C07AG01, labetalol, Pegvisomant may increase the bradycardic activities of Labetalol.]
[N04BB01, amantadine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Pegvisomant.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be increased when combined with Pegvisomant.]
[N06AA21, maprotiline, The therapeutic efficacy of Maprotiline can be decreased when used in combination with Pegvisomant.]
[C02BB01, mecamylamine, The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Pegvisomant.]
[R06AE05, meclizine, The therapeutic efficacy of Meclizine can be decreased when used in combination with Pegvisomant.]
[N02AB02, meperidine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meperidine.]
[N03AA01, mephobarbital, The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Pegvisomant.]
[N02AX05, meptazinol, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meptazinol.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metformin.]
[H01CB03, lanreotide, The risk or severity of increased transaminases can be increased when Lanreotide is combined with Pegvisomant.]
[N07BC02, methadone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadone.]
[A03AB07, methantheline, The therapeutic efficacy of Methantheline can be decreased when used in combination with Pegvisomant.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Pegvisomant.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Pegvisomant.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone.]
[D07AC14, methylprednisolone aceponate, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone aceponate.]
[C07AB02, metoprolol, Pegvisomant may increase the bradycardic activities of Metoprolol.]
[G03XB01, mifepristone, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mifepristone.]
[N06AA09, amitriptyline, The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Pegvisomant.]
[N02AA01, morphine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.]
[L04AB05, certolizumab pegol, The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegvisomant.]
[M03AC03, vecuronium, The therapeutic efficacy of Vecuronium can be decreased when used in combination with Pegvisomant.]
[N05CA02, amobarbital, The therapeutic efficacy of Amobarbital can be decreased when used in combination with Pegvisomant.]
[N06AA17, amoxapine, The therapeutic efficacy of Amoxapine can be decreased when used in combination with Pegvisomant.]
[C07AA12, nadolol, Pegvisomant may increase the bradycardic activities of Nadolol.]
[N02AF02, nalbuphine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nalbuphine.]
[N07BB04, naltrexone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Naltrexone.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Duloxetine.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegvisomant.]
[N01AH06, remifentanil, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Remifentanil.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Repaglinide.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Desvenlafaxine.]
[C08CA04, nicardipine, The therapeutic efficacy of Nicardipine can be decreased when used in combination with Pegvisomant.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Pegvisomant is combined with Nicotine.]
[N06AA10, nortriptyline, The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Pegvisomant.]
[H01CB02, octreotide, The risk or severity of increased transaminases can be increased when Octreotide is combined with Pegvisomant.]
[N02AA02, opium, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Opium.]
[C07AA02, oxprenolol, Pegvisomant may increase the bradycardic activities of Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxycodone.]
[N02AA11, oxymorphone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxymorphone.]
[A03AB03, oxyphenonium, The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Pegvisomant.]
[N02AX06, tapentadol, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tapentadol.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be decreased when used in combination with Pegvisomant.]
[H02AB05, paramethasone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Paramethasone.]
[G04BD11, fesoterodine, The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Pegvisomant.]
[C07AA23, penbutolol, Pegvisomant may increase the bradycardic activities of Penbutolol.]
[N02AD01, pentazocine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Pegvisomant.]
[N02AD02, phenazocine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Phenazocine.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Phenformin.]
[N03AA02, phenobarbital, The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Pegvisomant.]
[N01AH04, phenoperidine, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Phenoperidine.]
[S01EB01, pilocarpine, The risk or severity of adverse effects can be increased when Pegvisomant is combined with Pilocarpine.]
[C07AA03, pindolol, Pegvisomant may increase the bradycardic activities of Pindolol.]
[A02BX03, pirenzepine, The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Pegvisomant.]
[N02AC03, pirinitramide, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Piritramide.]
[N02CX01, pizotyline, The therapeutic efficacy of Pizotifen can be decreased when used in combination with Pegvisomant.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Rosiglitazone.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegvisomant.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Saxagliptin.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin lispro.]
[C07AB01, practolol, Pegvisomant may increase the bradycardic activities of Practolol.]
[S03BA02, prednisolone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisolone.]
[H02AB07, prednisone, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisone.]
[N03AA03, primidone, The therapeutic efficacy of Primidone can be decreased when used in combination with Pegvisomant.]
[S01HA05, procaine, Pegvisomant may increase the neuromuscular blocking activities of Procaine.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Pegvisomant.]
[N05AA03, promazine, The therapeutic efficacy of Promazine can be decreased when used in combination with Pegvisomant.]
[R06AD02, promethazine, The therapeutic efficacy of Promethazine can be decreased when used in combination with Pegvisomant.]
[C01BC03, propafenone, Pegvisomant may increase the bradycardic activities of Propafenone.]
[A03AB05, propantheline, The therapeutic efficacy of Propantheline can be decreased when used in combination with Pegvisomant.]
[N05CM06, propiomazine, The therapeutic efficacy of Propiomazine can be decreased when used in combination with Pegvisomant.]
[N02AC04, propoxyphene, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextropropoxyphene.]
[C07AA05, propranolol, Pegvisomant may increase the bradycardic activities of Propranolol.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Pegvisomant.]
[A03AB15, diphemanil, The therapeutic efficacy of Diphemanil can be decreased when used in combination with Pegvisomant.]
[A03AB09, isopropamide, The therapeutic efficacy of Isopropamide can be decreased when used in combination with Pegvisomant.]
[S01FA03, methscopolamine, The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Pegvisomant.]
[N05CA07, talbutal, The therapeutic efficacy of Talbutal can be decreased when used in combination with Pegvisomant.]
[C01BA01, quinidine, The therapeutic efficacy of Quinidine can be decreased when used in combination with Pegvisomant.]
[P01BC01, quinine, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Quinine.]
[S01FA02, scopolamine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Pegvisomant.]
[N05CA06, secobarbital, The therapeutic efficacy of Secobarbital can be decreased when used in combination with Pegvisomant.]
[C05BB02, polidocanol, The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegvisomant.]
[H01CB01, somatostatin, The risk or severity of increased transaminases can be increased when Somatostatin is combined with Pegvisomant.]
[C07AA07, sotalol, Pegvisomant may increase the bradycardic activities of Sotalol.]
[D07AB02, hydrocortisone butyrate, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone butyrate.]
[R03BB01, ipratropium bromide, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Pegvisomant.]
